FDA Approves Centanafadine for ADHD - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Centanafadine for ADHD

The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.

  • By

  • Kathryn Wighton

  • July 27, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Centanafadine for ADHD

  • by Kathryn Wighton

  • July 27, 2026

Related Content

Effectiveness of WeChat Public Account Intervention Based on the Information-Motivation-Behavioral Skills Model Among College Students With Internet Addiction: Randomized Controlled Trial

Machine learning–based prediction of suicide attempts among adolescents: a national study using explainable artificial intelligence

Machine learning-based nomogram for non-suicidal self-injury among depressed adolescents: a multicentre study